

Testing

The plaintiff argued that the Superior Court's decision to reject negligent testing as a cause of action is in conflict with the 1973 prediction by the 3rd U.S. Circuit Court of Appeals in *Hoffman v. Sterling Drug Inc.* that Pennsylvania would allow a claim for negligent failure to test to be asserted against a prescription drug manufacturer.

The plaintiff also argued that all six judges, on an equally divided en banc Superior Court panel, said in *Leibowitz v. Ortho Pharmaceutical Corp.* that a drugmaker can't escape liability by "merely ignoring existing reports of side-effects or dangers in the use of its product."

Barring the theory of negligent failure to test may make sense in the context of a prescription drug that has a benefit that outweighs "its actual but undisclosed dangers," but the theory is cognizable in the case of a drug like Redux in which the medication's risks outweighs the benefits "as to all possible classes of plaintiffs," the plaintiff said in her brief.

"What makes this case and other cases involving these Fen-Phen drugs different from the typical, run-of-the-mill prescription drug failure to warn cases is that these medications have subsequently been entirely banned from the market by the FDA," Lance argued in court papers. "In other words, there is no risk-benefit balancing test that can be performed with respect to Redux that would allow anyone to conclude that this medication should be, or ever should have been, available to any class of patients, as demonstrated by the FDA's decision completely banning this drug from the market."

Pfizer argues that the Supreme Court's decision in *Hahn* and in other cases recognized a failure to warn as the only cognizable claim against the seller of "properly manufactured drug." But Lance argues that *Hahn* barred strict liability claims against drugmakers, not other negligence claims besides failure to warn claims.

Design

The Superior Court panel concluded the *Restatement (Second) of Torts* , Section 395, which regards a negligent design of products, does not provide special protection for prescription drugs, *The Legal* previously reported.

Citing an Idaho Supreme Court decision from 1987 and a California appeals court decision from 1994, the court said that "a negligent design defect claim is considered to be distinct from a strict liability design defect claim."

Pfizer's first argument against the negligent design defect theory is procedural. The company said in its brief that the specific issue was not presented in the trial court of the intermediate appellate court, including in the plaintiff's statement of issues, the plaintiff's briefing in opposition to the defense motion for summary judgment and in the plaintiff's statement of questions presented to the Superior Court.

Secondly, on a different view of the law than espoused by the Superior Court, Pfizer looked to Comment K of the *Restatement (Second) of Torts* , Section 402A, rather than Section 395, arguing that Comment K gives special treatment to prescription drugs. The Supreme Court's adoption of Comment K "reflects a policy judgment by this court that prescription drugs, as a category, are 'unavoidably unsafe,'" Pfizer said in its brief. "Put simply, prescription drugs are different from other products — drugs inevitably carry some risk accompanying the benefits they provide, which is why they require a physician's prescription."

Lance argued that Comment K requires that the prescription drugs are "properly prepared and marketed, and proper warning is given."

Thirdly, Pfizer said the new cause of action does not require plaintiffs to provide the existence of a feasible alternative design or show the necessary deference to the FDA about the safety of prescription drugs.

"The Superior Court's decision potentially greatly expands liability against prescription drug manufacturers," Pfizer argued in its brief. "In fact, plaintiff's failure to put forth any 'feasible alternative design' makes clear that her 'negligent design defect' cause of action is nothing more than a disguised claim that Redux should never have been approved by the FDA, or should have been withdrawn sooner than it was — a claim even the Superior Court recognized that is not cognizable under Pennsylvania law."

Howard Bashman, the appellate counsel for the plaintiff and a Willow Grove, Pa., solo practitioner, said "the defendants have been arguing the only type of negligent claim they can be liable for is negligent failure to warn. It's our position that's not what Pennsylvania law says."

Bashman said that they were encouraged recently by a Superior Court decision in *Wright v. Aventis Pasteur* that a negligent design defect claim could be sustained against the manufacturers of vaccines. The court found that some design defect claims that arise from unavoidable vaccine side effects are pre-empted by federal law.

That ruling would seem to allow recognition of negligent design defect claims for prescription drug manufacturers, Bashman said. Bashman writes an appellate law column for *The Legal* .

Pfizer counsel Robert C. Heim, of Dechert, said that "we were very happy that the court decided to take this because the Superior Court had seemed to be creating a whole new cause of action that had never been argued or briefed to the Superior Court and which has never been a part of Pennsylvania law: this theory of negligent design defect in a prescription drug."

Advertisement

lawjobs.com

TOP JOBS

Corporate Associate
Duane Morris LLP
Philadelphia, Pennsylvania

LITIGATION ASSOCIATE
DAVIS & BUCCO, P.C.
Conshohocken, Pennsylvania

MORE JOBS
POST A JOB

Advertisement



Click here to watch our free on-demand webinar:
Practical Tips to Drive Down the Cost of eDiscovery

Co-counsel for Lance are Linda C. Love and Michael L. Williams of Williams Love O'Leary & Powers in Portland, Ore.



Co-counsel for Pfizer are Judy L. Leone and Will W. Sachse of Dechert.



Two other cases, *Owens v. Wyeth* and *Cochran v. Wyeth*, decided by the same Superior Court panel and also presenting issues of first impression, are still pending in front of the Supreme Court. •



Subscribe to The Legal Intelligencer



Print Share Email Reprints & Permissions Post a Comment



From the Law.com Network



Discovery Infocenter
A highly efficient discovery process translates to a high quality response. Access featured discovery articles, whitepapers, interviews, and webcasts to improve your discovery process and performance. [Learn More.](#)



Cantil-Sakaue Wants to Shake Things Up
9th Circuit Splits on Value of Lying



Jeffrey Epstein's alleged victims want secret deal nixed
Involuntary bankruptcy filed against ex-trustee Tolz



Unsigned Confessions Can Be Used To Assist Witnesses During Trial
Kelley Drye Disqualified Over Access to Ex-Client's Confidential Documents



The 2010 Electronic AmLaw 200
These reports have become an industry standard for determining benchmark success within law firms.

the LAW.COM network

Advertise

LAW.COM Newsire Special Reports International News Small Firms Lists, Surveys & Rankings Legal Blogs	ALM REGIONAL Connecticut Law Tribune Daily Business Review (FL) Delaware Law Weekly Daily Report (GA) The Legal Intelligencer (PA) New Jersey Law Journal New York Law Journal GC New York New York Lawyer The Recorder (CA) Texas Lawyer	DIRECTORIES ALM Experts LegalTech® Directory In-House Law Departments at the Top 500 Companies New York's Women Leaders in the Law Corporate Counsel: Best Lawyers® Annual Guides The American Lawyer: Best Lawyers® Annual Guides The National Law Journal Leadership Profiles	BOOKS & NEWSLETTERS Best-Selling Books Publication E-Alerts Law Journal Newsletters LawCatalog Law Journal Press Online	EVENTS & CONFERENCES ALM Events LegalTech® Virtual LegalTech® Virtual Events Webinars & Online Events Insight Information
ALM NATIONAL The American Lawyer The Am Law Litigation Daily Corporate Counsel Law Technology News Minority Law Journal The National Law Journal			RESEARCH ALM Legal Intelligence Court Reporters MA 3000 Verdict Search ALM Experts Legal Dictionary Smart Litigator	REPRINTS Reprints ONLINE CLE CLE Center CAREER Lawjobs